A Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Doses of LY3322207 in Healthy Subjects and Subjects With Hypertension on ACE I/ARB Therapy
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs LY-3322207 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 22 Feb 2019 Status changed from recruiting to discontinued.
- 03 Dec 2018 Planned End Date changed from 21 Jan 2019 to 13 May 2019.
- 03 Dec 2018 Planned primary completion date changed from 21 Jan 2019 to 13 May 2019.